Sign up Latest Topics

  Author   Comment  

Posts: 1,164
Reply with quote  #1 
To those in treatment with Prof ML at his private clinic and Dr RK at her NHS LUTS clinic. We have received the following message for patients. This will also provide an update on the supply issue in the UK around Hiprex for anyone using it whether they are a patient of these two specialists or not.

“We have spoken to a senior manager at the company that manufactures Hiprex (Methenamine). They are well aware of the problem of supply which originates from the fact that they were caught unawares by the surge in demand. They have trebled their production capacity but it will take time to filter through. We have provided them with a great deal of information on the prevalence of this condition and I am helping them to predict future demand. They are going to liaise closely with us going forward. We accept no payments or incentives from industry so that we can avoid any conflict of interest.

There is no alternative equivalent option to use instead so we must wait on supplies being re-established”.

Previous Topic | Next Topic

Quick Navigation:

Easily create a Forum Website with Website Toolbox.

This Forum is provided by Bladder Health UK and is intended as a place for Sufferers of Interstitial Cystitis, Bacterial Cystitis and Over Active Bladder, together with their family & friends to gather, online in a positive exchange.

BHUK is not a medical body & do not claim to have medical knowledge. It is not the intention of BHUK to provide specific medical advice, but to provide users with information to better understand their health & to manage their suffering.

Specific medical advice will not be provided & BHUK strongly advises that you consult your GP/Consultant/Urologist for professional advice.

We would hope that users of these forums will conduct themselves in a courteous and respectful manner. Any conduct not consistent with this standard will be deleted immediately and the poster may be restricted and/or terminated without warning.